Long Acting Reversible Contraception in Adolescents with Cardiovascular Conditions - 12/11/14
, Elizabeth A. Micks, MD, MPH 1, Katherine E. Debiec, MD 1, Tiana Nizamic, BS, BA 2, Malica D. Mantrala, MPH 2, Sarah W. Prager, MD, MAS 1Abstract |
Study Objective |
The purpose of this case series was to evaluate the efficacy and complication rate with use of long-acting reversible contraceptive (LARC) methods in adolescents with cardiovascular conditions.
Design and Participants |
We performed a retrospective chart review of adolescents age 22 or younger with congenital cardiac anomalies or major cardiovascular conditions who had a LARC device placed at Seattle Children’s Hospital or University of Washington Medical Center between January 1, 2007 and March 1, 2012.
Main Outcome Measures |
Patient characteristics, medical conditions, indications, and complications including perforation, pregnancy, expulsion, and pelvic infection were collected and analyzed.
Results |
Thirty adolescents with congenital cardiac anomalies or other cardiovascular conditions had a LARC device inserted during the study period. Mean age at placement was 17.7 years (range 12-22). Twelve patients (40%) had reported a previous pregnancy and 12 (40%) had never been sexually active at time of placement. Common primary and secondary indications were desired contraception (22 patients, 73%), desired menstrual suppression (15 subjects, 50%) and treatment of heavy menstrual bleeding (8 subjects, 27%). Twenty-nine patients had a structural cardiac anomaly. There were 27 levonorgestrel-releasing intrauterine devices (IUD), 1 copper IUD, and 3 etonogestrel implants placed. There were 2 confirmed IUD expulsions and 1 removal due to persistent irregular bleeding and cramping. There were no cases of pelvic inflammatory disease or pregnancies with LARC methods in place. Twenty-seven (90%) patients were continuing LARC at last follow-up.
Conclusions |
In this small case series of adolescents with cardiovascular conditions, LARC devices were effective at pregnancy prevention without serious complications.
Le texte complet de cet article est disponible en PDF.Key Words : Intrauterine device, Etonogestrel implant, Cardiac, Cardiovascular, Adolescent, Contraception
Plan
| Dr. Elizabeth Micks received the ACOG/Bayer HealthCare Pharmaceuticals Research Award in Long Term Contraception in 2011, an unrestricted award given by ACOG and funded by Bayer. Moneys from this award were not applied toward this research study. |
Vol 27 - N° 6
P. 353-355 - décembre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
